Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Progress
Nature Reviews Cancer 9, 321–326 (1 May 2009) | doi:10.1038/nrc2615
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics
&
Abstract
Therapeutic targeting of tumours on the basis of molecular analysis is a new paradigm for cancer treatment but has yet to fulfil expectations. For many solid tumours, targeted therapeutics, such as inhibitors of oncogenic kinase pathways, elicit predominantly disease-stabilizing, cytostatic responses, rather than tumour regression. Combining oncogenic kinase inhibitors with direct activators of the apoptosis machinery, such as the BH3 mimetic ABT-737, may unlock potent anti-tumour potential to produce durable clinical responses with less collateral damage.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
